CA2630900A1 - Use of parp-1 inhibitors - Google Patents

Use of parp-1 inhibitors Download PDF

Info

Publication number
CA2630900A1
CA2630900A1 CA002630900A CA2630900A CA2630900A1 CA 2630900 A1 CA2630900 A1 CA 2630900A1 CA 002630900 A CA002630900 A CA 002630900A CA 2630900 A CA2630900 A CA 2630900A CA 2630900 A1 CA2630900 A1 CA 2630900A1
Authority
CA
Canada
Prior art keywords
composition
parp
amount
inhibitor
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002630900A
Other languages
English (en)
French (fr)
Inventor
Kathleen A. Scotto
Michael Mandola
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2630900A1 publication Critical patent/CA2630900A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002630900A 2005-11-25 2006-11-27 Use of parp-1 inhibitors Abandoned CA2630900A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73953605P 2005-11-25 2005-11-25
US60/739,536 2005-11-25
PCT/US2006/061254 WO2007062413A2 (en) 2005-11-25 2006-11-27 Use of parp-1 inhibitors

Publications (1)

Publication Number Publication Date
CA2630900A1 true CA2630900A1 (en) 2007-05-31

Family

ID=38068066

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002630900A Abandoned CA2630900A1 (en) 2005-11-25 2006-11-27 Use of parp-1 inhibitors

Country Status (9)

Country Link
US (1) US20090170860A1 (enExample)
EP (1) EP1962843B1 (enExample)
JP (1) JP2009517403A (enExample)
AT (1) ATE499098T1 (enExample)
AU (1) AU2006318226A1 (enExample)
CA (1) CA2630900A1 (enExample)
DE (1) DE602006020335D1 (enExample)
ES (1) ES2361566T3 (enExample)
WO (1) WO2007062413A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
BR0115162A (pt) * 2000-11-06 2003-10-21 Pharma Mar Sa Tratamentos antitumorais eficazes
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
US20080255132A1 (en) * 2003-11-14 2008-10-16 Eric Rowinsky Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
PL1827500T3 (pl) * 2004-10-26 2009-09-30 Pharma Mar Sa Pegylowana liposomalna doksorubicyna w kombinacji z ekteinascydyną 743
DK1658848T3 (da) * 2004-10-29 2007-11-26 Pharma Mar Sa Formuleringer omfattende ecteinascidin og et disaccharid
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
US9486449B2 (en) 2007-10-09 2016-11-08 Malka COHEN-ARMON Cancer therapy
EP2207548B1 (en) * 2007-10-09 2013-05-22 Malka Cohen-Armon Breast cancer therapy
AU2008313634A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Prognostic molecular markers for ET-743 treatment
US8871765B2 (en) 2010-07-27 2014-10-28 Cadila Healthcare Limited Substituted 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one derivatives as poly (ADP-ribose) polymerase-1 inhibitors
EP2870140B8 (en) 2012-07-09 2016-09-28 Lupin Limited Tetrahydroquinazolinone derivatives as parp inhibitors
SG11201503670YA (en) 2012-12-31 2015-07-30 Cadila Healthcare Ltd Substituted phthalazin-1 (2h)-one derivatives as selective inhibitors of poly (adp-ribose) polymerase-1
CN106853252B (zh) * 2015-12-09 2020-03-13 江苏恒瑞医药股份有限公司 曲贝替定药物组合物及其制备方法
CN108368059B (zh) * 2016-04-18 2022-02-01 深圳市塔吉瑞生物医药有限公司 一种取代的酞嗪酮化合物及其药物组合物
KR20180097876A (ko) * 2017-02-24 2018-09-03 주식회사 온코크로스 1,5-이소퀴놀린디올을 포함하는 피부 노화 방지 및 주름 개선용 조성물
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
EP3960177A1 (en) * 2020-08-26 2022-03-02 Anturec Pharmaceuticals GmbH Composition comprising ttf-ngr for use in treating soft-tissue sarcoma

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635677B2 (en) * 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
BR0115162A (pt) * 2000-11-06 2003-10-21 Pharma Mar Sa Tratamentos antitumorais eficazes
JP4824566B2 (ja) * 2003-05-28 2011-11-30 エーザイ インコーポレーテッド Ｐａｒｐを阻害するための化合物、方法、および医薬組成物
GB0317466D0 (en) * 2003-07-25 2003-08-27 Univ Sheffield Use
US20050187172A1 (en) * 2003-12-23 2005-08-25 Masferrer Jaime L. Combination of a Cox-2 inhibitor and a DNA topoisomerase I inhibitor for treatment of neoplasia
PE20060285A1 (es) * 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)

Also Published As

Publication number Publication date
EP1962843A2 (en) 2008-09-03
EP1962843A4 (en) 2009-08-12
US20090170860A1 (en) 2009-07-02
WO2007062413A3 (en) 2007-12-27
JP2009517403A (ja) 2009-04-30
ATE499098T1 (de) 2011-03-15
DE602006020335D1 (de) 2011-04-07
WO2007062413A2 (en) 2007-05-31
AU2006318226A1 (en) 2007-05-31
EP1962843B1 (en) 2011-02-23
ES2361566T3 (es) 2011-06-20

Similar Documents

Publication Publication Date Title
EP1962843B1 (en) Use of parp-1 inhibitors
RU2478387C2 (ru) ИМИДАЗОХИНОЛИНЫ В КАЧЕСТВЕ ДВОЙНЫХ ИНГИБИТОРОВ ЛИПИДКИНАЗЫ И mTOR
US20200206188A1 (en) Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
US7361691B2 (en) Method of treating cancers using β-lapachone or analogs or derivatives thereof
JP2022088616A (ja) 再発性神経膠腫および進行性の二次性脳腫瘍からなる群から選択される悪性腫瘍の治療に使用するための薬剤の調製方法
CN101980708B (zh) 作为vegf驱动的血管生成过程的有效调节剂的咪唑并喹啉类及嘧啶衍生物
CN111053768B (zh) 用于治疗黑素瘤的药物组合
US20060270665A1 (en) Combination comprising an agent decreasing VEGF activity and an agent decreasing EGF activity
US9814724B2 (en) Antitumor effect potentiator and antitumor agent
KR101668931B1 (ko) 항종양제의 효과 증강제
US8481553B2 (en) Antimetastatic compounds
US20170258783A1 (en) Pfkfb3 inhibit and methods of use as an anti-cancer therapeutic
US20080139587A1 (en) Combinations Comprising Epothilones and Protein Tyrosine Kinase Inhibitors and Pharmaceutical Uses Thereof
HUP0303353A2 (hu) Profilaktikus és terápiás szer diabeteses komplikációkhoz
TW201242597A (en) A synergistic pharmaceutical combination for the treatment of pancreatic cancer
CN101171013A (zh) 嘧啶基氨基苯甲酰胺衍生物用于治疗全身性肥大细胞增多症的应用
MXPA06014477A (es) Agente antitumor, fortificador de efecto antitumor y metodo de terapia para cancer.
EP2298309B1 (en) Antitumor agent, kit and method of treating cancer
US20240252490A1 (en) Combination Therapies Comprising Kras Inhibitors and SPH2 Inhibitors
HK40026870A (en) A pharmaceutical combination for the treatment of melanoma
CN120960213A (zh) 氟伐他汀治疗紫杉醇耐药型非小细胞肺癌的新用途
HK40021582A (en) Use of alk inhibitor and egfr inhibitor in preparation of a medicine for treating cancer
HK40021582B (en) Use of alk inhibitor and egfr inhibitor in preparation of a medicine for treating cancer
TW201249843A (en) Processes for preparing amine salts of KMUP-3 and use thereof

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20121127